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following CATH and PCI, including settings in which use of contrast-sparing techniques
are standard of practice.
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Background: There is only limited and conflicting information about the impact of
pre-operative chronic kidney disease (CKD) on outcome after transcatheter aortic valve
implantation (TAVI). We sought to evaluate the impact of pre-operative CKD on clinical
outcome after TAVI, with either balloon- or self-expandable prosthesis, using transfemo-
ral or alternative access, in high risk patients with severe aortic stenosis.
Methods: We retrospectively analyzed pooled data from 4 centers’ prospective TAVI
databases (942 patients). VARC endpoint definitions were used. Patients were subdivided
into 4 categories of eGFR to examine the effect of: no ( 90 ml/min/1.73 m2), mild (61
to 90 ml/min/1.73 m2), moderate (31 – 60 ml/min/1.73 m2) and severe ( 30 ml/min/1.73
m2) CKD. To assess the effect of renal function on short- and long-term outcome,
univariable and multivariable logistic regressions were used; no-CKD category was the
reference category.
Results: No CKD was found in 109 patients (11.6%); 330 (35 %) had mild, 400 (42.4
%) moderate and 103 (11%) severe CKD. Baseline and procedural characteristics were
similar among all groups except for the Logistic EuroSCORE, incidence of severe left
ventricular dysfunction, anemia, and a transapical approach, which was higher when the
CKD was more severe. Major stroke (severe CKD: 4.9 %, moderate: 2.8 %, mild: 1.2 %,
no: 1.8 %, p0.05), life-threatening bleeding (severe CKD: 24.3%, moderate 14.8 %,
mild: 11.2 %, no: 8.3 %, p0.001), all-cause 30-day mortality (severe CKD 9.7%,
moderate 8.5%, mild 6.7%, no 1.7%, p0.02) and one-year mortality differed signifi-
cantly across CKD groups. By multivariate analysis, severe CKD (HR 4.21, 95 % CI
1.67-10.66) was an independant predictor of one-year mortality.
Conclusions: Patients with CKD who undergo TAVI have a higher risk profile and a
worse 30-day and one-year outcome. Severe CKD at baseline is an independent predictor
of 1-year mortality after TAVI.
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Background: Diagnosis of acute kidney injury (AKI) relies on a late marker, namely
serum creatinine (SCr). Several biomarkers are considered for an early and sensitive
detection of contrast-induced nephropathy (CIN). In particular, urinary Neutrophil
Gelatinase-Associated Lipocalin (uNGAL) has been used for early detection of AKI in the
emergency department, after cardiopulmonary bypass or following contrast medium
(CM) exposition. Our study was conducted to assess the value of uNGAL as an early
detector of CIN in patients undergoing percutaneous coronary procedures (PCP) and
whether or not uNGAL correlates with the volume of CM.
Methods: We enrolled 244 consecutive patients undergoing PCP with Iomeprolum at our
institution. CIN was defined as a25% increase in SCr from baseline when measured 2-4
days after PCP. uNGAL was measured at its peak (4-6 hours after PCP) with the Abbott
ARCHITECT assay.
Results: Among the patients (median[iqr] age 66.6[59.5-74.7] years, 70% male),
149(61%) underwent a diagnostic PCP and 95(39%) underwent a therapeutic PCP with a
median CM volume of 123[88-168] ml. 25(10%) patients developed CIN after PCP. We
found neither a significant difference in uNGAL levels between patients with and without
CIN (p0.20), nor a significant correlation between the CM volume versus uNGAL
levels (r-0.11) (Fig. 1).
Conclusions: In a large cohort of patients at low-risk for contrast-induced nephropathy,
urinary NGAL measured 4 to 6 hours after PCP was not useful in predicting the
development of contrast-induced nephropathy and did not correlate with the volume of
contrast medium used during the procedure.
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Background: Contrast-induced acute kidney injury (CI-AKI) continues to be an
important complication of contrast administration. We’ve recently discovered the utility
of substituted cyclodextrins (SCD) for mitigating the renal toxicity of several classes of
nephrotoxic agents including antibiotics, anticancer agents and contrast agents (CA). This
discovery is the basis for the development of Veropaque, a new contrast agent containing
iohexol and a SCD. Here we report on preclinical animal studies using several CAs and
SCDs.
Methods: Formulations containing iopamidol, iodixanol and iohexol were prepared
w/wo various amounts of sulfobutylether--cyclodextrin (SBECD) or 2-hydroxypropyl-
-cyclodextrin (HPCD). The formulations were dosed iv at 1.5 g Iodine/kg to renally
compromised (RC) mice and rats. Plasma samples were taken for creatinine analysis, and
kidney pathology was evaluated at 24 or 48h. A 14-day survival study in RC rats was also
conducted with 2.5g I/mL iv doses of iohexol or iohexol	SBECD (Veropaque). The
iohexol and Veropaque formulations were also rapidly injected into the left main coronary
artery of anesthetized instrumented dogs. ECG and hemodynamics were monitored.
Results: Small amounts of SCD added to CA formulations dramatically reduced the
kidney pathology in both rats and mice at 24 and 48h and preserved kidney function as
measured by plasma creatinine. The nephroprotection was observed for both SCDs and all
three CAs and was dose dependent on the SCD from CA:SCD mole ratios of 1:0.0125 to
1:0.05. The SCD also reduced mortality in the 14-day study (8/8 control, 4/8 iohexol, 7/8
Veropaque survived). Intracoronary injections in the dog model revealed no significant
differences between iohexol and Veropaque and no notable effects on most measured
cardiovascular parameters other than transient changes in LV contractility and QTc
interval as previously described in the literature.
Conclusions: SCDs are nephroprotective against CI-AKI pathology, functional changes,
and mortality in rodent models without altering the expected cardiac hemodynamic and
electrophysiologic effects of the CAs. Further development of Veropaque is warranted and
underway.
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Background: Few data are currently available about the characteristics and procedural
features associated with Acute kidney Injury (AKI) after Transcatheter Aortic Valve
Implantation (TAVI) using the new recommended Valve Academic Research Consortium
(VARC) definition.
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Methods: 99 patients underwent TAVI (78.8% trans-femoral, 12.1% trans-apical/aortic
and 9.1% subclavian access) between February 2009 and September 2011 at Rennes
University Hospital. Creatinine level was assessed daily at least up to 72 hours after
TAVI. the characteristics of patients, procedural features and outcomes according to
VARC definitions were studied to evaluate determinants and prognostic impact of AKI.
Results: AKI occurred in 22 patients (22.2%). Among them, 5 were AKI 2 (5.1%), 8
were AKI 3 (9.1%) including 4 who needed dialysis (4%). At baseline, compared to no
AKI or AKI 1, AKI 2 or 3 patients had a higher prevalence of  grade 2 mitral
regurgitation (p0.03). There was a non significant trend toward a higher prevalence of
moderate or severe chronic kidney disease (p0.07). During the post TAVI hospitaliza-
tion, AKI 2 or 3 was related to a higher rate of death from any cause (p0.0009), major
bleeding, acute heart failure (both p0.002), infectious complications (p0.0008) and
longer total and ICU hospitalization duration (p0.0004 and 0.0001 respectively).
There was no association between any stage of AKI and the 30-day and 6-months rate of
death. Only AKI 3 was associated with a higher risk of 6-months NYHA class III or IV
(p0.016).
Conclusions: AKI 2 or 3 as defined by the VARC criteria were associated with a higher
risk of post procedural death because of their association with other major post procedural
complications. AKI 3 was associated with a higher risk of short term worse functional
outcomes.
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Background: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) have
been demonstrated to be associated with poor outcomes following percutaneous coronary
intervention (PCI). Although there have been significant advances in PCI, patients with
CKD/ESRD are often excluded from the majority of published trials. To date, little is
known about the trend of clinical outcomes in this population who have undergone PCI.
Methods: We analyzed data from 2,470 patients with CKD or ESRD who underwent
PCI at The Cleveland Clinic between 1992 and 2011. The primary outcomes of our study
were the hard endpoints of all-cause death at 30 days, myocardial infarction (MI), stroke,
bleeding, and the composite of major adverse cardiovascular events (MACE), defined as
all-cause death at 30 days, MI, stroke, and bleeding. Patients were stratified into 3 groups
according to the time of their intervention: group 1 (1992-2000), group 2 (2001-2006),
and group 3 (2007-2011).
Results: Results are shown in Table 1. Over the 12 year period, there was a significant
decrease in the rates of bleeding (group 1: 19.3%, group 2: 12.6%, group 3: 9.3%,
p0.00001), MI (7.7%, 3.9%, 2.0%, p 0.0001) and MACE (27.1%, 18.3%, 15.1%,
p0.00001). Although rates of stroke and mortality were lower in the 2 most recent
cohorts compared with those patients treated before, this trend was not statistically
significant.
Conclusions: In a large registry of patients with CKD and ESRD who have undergone
PCI, the trend in clinical outcomes of bleeding and MI have improved over a span of 12
years. Further studies are warranted to understand contributing factors for these improve-
ments.
Table 1 Clinical outcomes following PCI
Variable
1992-2000,
n  771 (%)
2001-2006,
n  965 (%)
2007-2011,
n  734 (%) p Value
Transfusion 149 (19.3) 122 (12.6) 68 (9.3) 0.00001
Stroke 8 (1.0) 2 (0.2) 4 (0.5) 0.07
NSTEMI 59 (7.7) 38 (3.9) 15 (2.0) 0.0001
Death
(30-days)
54 (7.0) 47 (4.9) 46 (5.4) 0.15
MACE 209 (27.1) 177 (18.3) 111 (15.1) 0.00001
MACE  major adverse cardiac event (transfusion, stroke, MI, and death at 30-days)
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Background: In patients undergoing primary PCI for STEMI, the occurrence of CIN has
a pronounced impact both on morbidity and mortality. We investigated the variables
associated with the development of CIN in patients with STEMI undergoing primary PCI.
We then evaluated the predictive accuracy of a 3-variable clinical risk score (the AGEF
score) based on age, left ventricular ejection fraction (LVEF) and estimated glomerular
filtration rate (eGFR), as compared with EuroSCORE and Mehran Risk Score (MRS).
Methods: 481 consecutive patients with STEMI who were undergoing primary PCI were
prospectively enrolled. CIN was defined as an absolute increase in serum creatinine0.5
mg/dL or an increase 25% from baseline within 72 hours after the administration of
contrast medium. AGEF score was calculated by adding 1 point to the Age/EF(%) ratio
if the eGFR was 60 mL/min per 1.73 m2. Logistic regression, receiver-operating
characteristic (ROC) curve analysis and Hosmer-Lemeshow 2 statistic were performed
to assess accuracy and calibration of AGEF score, EuroSCORE and MRS as predictors of
CIN.
Results: The incidence of CIN was 5.2%. In-hospital mortality was higher among
patients with CIN (16% Vs 1.3%, p0.001). At multivariable analysis age (OR 1.08,
p0.038), eGFR (OR 0.95, p0.002), LVEF (OR 0.94, p0.033) and post-procedural
TIMI flow (OR 0.30, p0.01) were independent predictors of CIN. AGEF score was an
accurate (OR 5.19, 95% CI 3.13-8.62, p0.0001, AUC 0.88) and well calibrated
(Hosmer-Lemeshow 210.24, p0.62) predictor of CIN with a 100% sensitivity for
AGEF score1.5 point; all patients developing CIN were in the highest tertile of AGEF
score (p0.0001). MRS (OR 1.27, p0.0001) and EuroSCORE (OR 1.61, p0.0001)
were less accurate, though not significantly, predictors of CIN than AGEF score.
Conclusions: Age, LVEF and eGFR are independent predictors of CIN development
after primary PCI for STEMI. A simple model based on pre-procedural, readily obtainable
variables, such the AGEF score, can predict the risk of CIN at least as accurately as more
complex non-linear risk scores and is well fitted to the acute settings. Complex risk
models may be over fitted, at least in populations with a low rate of events.
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Background: Acute kidney injury (AKI) post TAVR has been associated with increased
post operative morbidity and mortality. Long-term outcomes after TAVR with the
Edwards Sapien valve (Edwards Lifesciences, Irvine, CA) in patients who develop AKI
postoperatively are not well-described.
Methods: A retrospective analysis of 317 TAVR cases performed at Medical City
Hospital, Dallas, Texas from August 2006 through April 2012 was performed. The
incidence of AKI as per VARC criteria, multivariate predictors of AKI, and association
of AKI with one year mortality were evaluated.
Results: Stage 1 AKI occurred in 4.4% of patients (14/317), stage 2 in 28.7% (91/317),
and stage 3 in 4.4% (14/317). The overall operative mortality was 7.6%, with a mortality
of 2.5% in patients with no kidney injury, 21.4% in stage 1, 11.0% in stage 2, and 42.9%
in stage 3. The incidence of new postoperative dialysis was 2.5%. The one year
Kaplan-Meier survival is shown in Figure 1. Survival at 1 year for No injury/Stage 1/Stage
2/Stage 3 was 86  3 %, 64  13 %, 68  5%, and 43  13%, respectively. Logistic
regression modeling for the combination of Stage2 or Stage 3 AKI post-surgery
demonstrated that the last preoperative creatinine (for each 1 mg/dL increase, odds ratio 
2.21; 95% CI 1.26-3.85; p  0.001) and having a transapical approach (compared to
transfemoral, odds ratio  2.38; 95% CI 1.45-3.90; p  0.005) were significant
predictors for AKI. At 1 year,
Conclusions: AKI post TAVR is associated with increased postoperative and one-year
mortality. Further research regarding methods to prevent AKI can improve outcomes of
this procedure.
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